ProAxsis ProAxsis is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis has already registered a CE Mark in Europe for its ProteaseTag® Active Neutrophil Elastase Immunoassay as a biomarker of infection and inflammation in patients with chronic respiratory diseases such as bronchiectasis, COPD and cystic fibrosis. The company has now been successful with a recent application to theBioMedical Catalyst competition.

Recent Posts

Have Any Questions?

Contact Us


Share This :